The study, funded by the UK Government's Department of Trade and Industry, is led by Dr Colin McGuckin and Dr Nico Forraz from Kingston University's School of Life Sciences. It represents a significant step forward in the fast-developing field of stem cell research. Until now, experts have struggled to find a supply of cells in sufficient numbers that does not offend previous critics of stem cell research. The latest advance looks set to overcome such difficulties.
The trans-Atlantic team has been working with Drs Randall Urban, Larry Denner and Ronald Tilton from the University of Texas Medical Branch in Galveston. They have been using bioreactors at the Synthecon Corporation base in Houston enabling them to produce stem cells sharing many of the same characteristics as cells found in embryos. Research has so far relied on so-called adult cells found in blood and bone marrow from birth onwards or cells grown from embryos. The new type detected by the team harnesses the benefits of both. "We have found a unique group of cells that bring together the essential qualities of both types of stem cells for the first time," Dr McGuckin said.
The researchers findings may bring renewed hope to people awaiting treatment for a range of serious illnesses such as Diabetes, Alzheimer's Disease and multiple sclerosis. "Acquiring stem cells from embryos also has major limitations because it is difficult to obtain enough cells to transplant as well as getting the right tissue type for the patient," Dr McGuckin said. "Using cord blood gets over that obstacle because we can produce more stem cells and, with a global birth rate of 100 million babies a year, there is a better chance of getting the right tissue type for the many patients out there waiting for stem cell therapy. There is also far less likelihood of such cells being rejected when they are transplanted into people with liver disease, for example."
The team has taken its first steps towards proving its claims by growing defined liver tissue using the new cell type. By making use of special NASA-derived technology, the team is able to cultivate greater numbers of cells in equipment mimicking the effects of space microgravity. "Using Synthecon's bioreactors, originally designed by NASA, means the cells are able to expand faster, giving us a greater supply to work with," Dr Forraz said. "This system provides more cells for more tests, so we have the potential to make significant progress in applying the new cells to cure difficult to treat conditions such as juvenile diabetes, stroke, heart and liver disease."
Dr Urban who chairs UTMB's Internal Medicine department and serves as director of its Stark Diabetes Centre said he looked forward to the next phase of what was proving to be a fruitful collaboration. "We plan to use this technology to engineer pancreatic tissue as we work towards our goal of developing a cure for type 1 diabetes," he added.
The team's report will be published in the Cell Proliferation Journal on 18 August.
For further information, please contact Michael Williams at the Kingston University Press Office on +44 (0)20 8547 7952 or email email@example.com. Alternatively, please call Jim Kelly at the UTMB Office of Public Affairs on (409) 772-8791 or email firstname.lastname@example.org.
A report outlining the scientists' findings can be viewed at www.blackwell-synergy.com.
Further information on stem cell research being undertaken at Kingston University can be found at www.kingston.ac.uk/bpsrg. Additional details about latest developments at UTMB can be found at http://intmed.
Kingston University: With more than 18,000 students, Kingston University is the largest provider of higher education in South West London, offering an extensive range of undergraduate and postgraduate programmes. Government assessors have rated the University's teaching quality as excellent in 16 subject areas. In its most recent league table, The Sunday Times highlighted Kingston's teaching quality, describing it as a vocational university with a fine teaching record and praised the University for producing some of the best paid graduates in the United Kingdom.
UTMB: The University of Texas Medical Branch at Galveston (UTMB) opened in 1891. It was Texas' first medical school and is recognised as a major academic heath centre. Among its areas of research strength are infectious diseases, vaccine development, neuroscience, pain management and stroke treatment, gastro-intestinal health, environmental health and asthma, cancer, molecular medicine, aging and diabetes. UTMB's Nelda C. and H.J. Stark Diabetes Center was opened in June 2001 following a generous grant from the Stark Foundation of Orange, Texas.